Table 1 Patient baseline characteristics and demographics

From: Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Characteristic

Lenalidomide-treated (n=295)

Untreated (n=125)

Year of diagnosis, range

1977–2007

1983–2009

 Before 1990, n (%)

5 (1.7)

10 (8.0)

 1990–1999, n (%)

55 (18.6)

39 (31.2)

 2000–2009, n (%)

235 (79.7)

76 (60.8)

Median time from diagnosis to study entry (range), years

2.7 (0.1–29.2)

0

Median age (range), years

65 (32–94)

66 (30–91)

Male, n (%)

87 (29.5)

40 (32.0)

French-American-British classification, n (%)

 Refractory anemia

216 (73.2)

96 (76.8)

 Refractory anemia with ringed sideroblasts

21 (7.1)

10 (8.0)

 Refractory anemia with excess blasts

54 (18.3)

19 (15.2)

 Other or missing

4 (1.4)

0

Bone marrow blast count 5–10%, n (%)

31 (10.5)a

20 (16.0)

Cytogenetics, n (%)

 Isolated del(5q)

224 (75.9)

104 (83.2)

 del(5q) plus 1 additional abnormality

53 (18.0)

16 (12.8)

 del(5q) plus >1 additional abnormality

16 (5.4)

5 (4.0)

 Missing

2 (0.7)

0

Patients with WHO-defined isolated del(5q), n (%)b

160 (54.2)

85 (68.0)c

IPSS risk, n (%)d

 Low

104 (35.3)

50 (40.0)

 Intermediate-1

139 (47.1)

66 (52.8)

 Missing data

52 (17.6)

9 (7.2)

Median RBC transfusion burden (range), units/8 weeks

6 (1–25)

2 (1–10)e

Median hemoglobin level (range), g/dl

8.3 (4.3–12.7)

8.1 (3.0–12.3)

Median platelet count (range), × 109/l

245 (51–1 275)

261 (55–1 540)

Median neutrophil count (range), × 106/l

2170 (590–20 980)

2390 (510–28 782)

  1. Abbreviations: IPSS, International Prognostic Scoring System; RBC, red blood cell; WHO, World Health Organization.
  2. aData not available for 50 patients.
  3. bDefined as patients who had isolated del(5q) and <5% bone marrow blasts.
  4. cP<0.05 vs lenalidomide-treated patients.
  5. dInformation on whether patients had IPSS Low- or Intermediate-1-risk disease was available for 243 lenalidomide-treated and 116 untreated patients. The remaining patients had either Low- or Intermediate-1-risk disease, but exact IPSS scores were not clearly definable due to missing data.
  6. eData not available for 20 patients (French registry); P<0.001 vs lenalidomide-treated patients.
Back to article page